STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia

The STYLE Trial is a prospective, randomized, multi-center device trial intended to evaluate
the safety and efficacy of the Celution and Puregraft Systems in the processing and
preparation of an autologous fat graft enriched with adipose-derived regenerative cells
(ADRCs) in the treatment of early alopecia androgenetica. Patients may be included if they
are undergoing an elective cosmetic liposuction. Following informed consent and screening
evaluations, eligible subjects will undergo pre-operative testing. Subjects will then undergo
a fat harvest using local anesthesia with or without conscious sedating. Subjects will be
randomly assigned to receive a fat graft cell enriched with ADRCs (available in two different
doses),a fat graft without cell enrichment using a visually-matched blood saline solution
(fat alone control), or a saline injection (no-fat control) in a 2:2:2:1 ratio.

While undergoing liposuction, lipoaspirate will be processed in the Puregraft System to
remove the lipoaspirate of impurities and in the Celution System to isolate and concentrate
ADRCs. After the liposuction is completed), patients will have, under a ring block local
anesthesia (see further description below), a subcutaneous scalp injection of either
Puregraft purified autologous fat or saline (no-fat control) followed by a separate second
injection, of either ADRCs (available in two different doses),a visually-matched blood saline
solution (fat alone control), or saline (no-fat control) in a 2:2:2:1 ratio.

The STYLE Clinical Trial will have a sample size of 70 patients at up to eight (8) centers.

Inclusion Criteria:

1. Males with a diagnosis of Alopecia Androgenetica

2. Females with a diagnosis of Alopecia Androgenetica

3. Males with hair loss consistent with Grades III, IIIA, III-Vertex, IV, IV-A, based on
Norwood-Hamilton Scale (Figure 1)

4. Females with hair loss consistent with Grades I-3, I-4, II-1, II-2 based on the Savin
Scale (Figure 2)

5. Provide written informed consent and comply with the study requirements

6. For women of childbearing potential: Negative pregnancy test at screening visit plus
subject agrees to maintain two forms of contraception for the duration of the study.

7. Subject is willing to maintain a consistent hair length and natural hair color,
without the use of any coloring agents, during the study period.

8. Ability to complete study procedures, patient surveys, and pictures.

9. Subject is ≥ 18 years of age.

10. Body Mass Index < 40kg/m2

Exclusion Criteria:

1. Subjects who have used minoxidil, or any oral or topical medication including over the
counter and herbal medications for the treatment of hair loss within 6 months of study
screening, or finasteride or dutasteride within 12 months of study screening

2. Treatment with an investigational product or procedure within 30 days or plans to
participate in another clinical study

3. Subject who has previously failed or has been deemed non-responsive to a previous
experimental hair loss treatment.

4. Subject must have no previous hair transplant, cell treatment, micro needling, or any
other treatment in the last 6 months in the scalp.

5. Subject is currently suffering from an active autoimmune disease such as serum lupus
erythematosus, or alopecia areata. Subject is currently suffering from dermatologic
condition in the treatment area or has a significant scar in the hair treatment area
that, in the opinion of the investigator, will make hair growth difficult (such as
systemic burns, etc.).

6. History of autoimmune disease or organ transplantation or a patient on
immunosuppressive medication(s).

7. Diagnosis of cancer, receiving active treatment

8. Active systemic infection

9. Requires chronic antibiotics, systemic corticosteroids

10. Use of systemic agents that increase bleeding or clotting, or disorders associated
with these effects, including patients receiving GIIB/IIIa inhibitors within 2 weeks
prior to the study procedure through to 1 week after the study procedure.

11. Clinically significant medical or psychiatric illness currently or within 30 days of
study screening as determined by the investigator

12. Prior surgery in the treatment area

13. Any disease or condition (medical or surgical) that, in the opinion of the
investigator, might compromise dermatologic, hematologic, cardiovascular, pulmonary,
renal, gastrointestinal, hepatic, or central nervous system function; or any condition
that would place the subject at increased risk

14. Pregnant or lactating women or women trying to become pregnant

15. Known allergic reaction to components of study treatment and/or study injection
procedure

16. Subject has any disorder that may prevent compliance to study procedures and visits

17. Subject who is part of the study staff, a family member or friend

18. Diabetes or thyroid disorder

19. Subject who has a sensitive, irritated, or abraded scalp area.

20. Women who have an alternate diagnosis that is associated with hair loss.

21. Body Mass Index < 18kg/m2

22. Clinically significant abnormal findings on laboratory screening panels, including
hemoglobin ≤ 10 g/dL.

23. Hepatic dysfunction, as defined as aspartate aminotransferase (AST), alanine
aminotransferase (ALT), or bilirubin levels > 1.5 times the upper limit of normal
range (x ULN) prior to randomization.

24. Chronic renal insufficiency as defined as a serum creatinine > 1.2 mg/dL for women and
> 1.5 mg/dL for men.

25. An elevated PT/PTT, INR, or platelet count < 100 x 109/L